New Five-Year Data Support Superiority of Novartis Drug Tasigna® Over Gleevec …
New five-year data support superiority of Novartis drug Tasigna® over Gleevec …
The Novartis treatment-free remission (TFR) clinical trial program includes eight studies that are now underway and actively enrolling Ph+ CML patients in more than 100 study centers across 40 countries5. In total, it is planned that more than 2,500 …
Read more on MarketWatch